Latest brain research, tools and teasers to think outside the mental health status quo box

By SharpBrains | February 26, 2020

__ Time for a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing a range of  research find­ings, resources, brain teasers and rid­dles to help trans­late emerg­ing neu­ro­science into real-world appli­ca­tions and improve our col­lec­tive brain & men­tal health. New think­ing: Neu­ro­science tips about grat­i­tude, aging, pain and the brain: An inter­view with Dr. Daniel Lev­itin What’s normal?…

Read More

Large study finds positive yet mixed results from Akili’s digital therapeutic for kids with ADHD

By SharpBrains | February 25, 2020

__ Full pub­li­ca­tion of piv­otal tri­al data out­lines Akil­i’s case for FDA reg­u­la­tion (Mobi­Health­News): “A full tran­script of STARS-ADHD — the piv­otal tri­al of Akili Interactive’s video game-like pedi­atric atten­tion deficit treat­ment — has been pub­lished in The Lancet Dig­i­tal Health jour­nal, pro­vid­ing onlook­ers a clear view of data fuel­ing the dig­i­tal ther­a­peu­tic company’s pending…

Read More

Study finds combined pharma + non-pharma treatment most beneficial to help youth with ADHD address long-term academic difficulties

By Dr. David Rabiner | February 10, 2020

__ Aca­d­e­m­ic dif­fi­cul­ties are one of the most impor­tant adverse con­se­quences of ADHD, and they fre­quent­ly con­tribute to par­ents’ deci­sion to seek treat­ment for their child. Whether treat­ment con­sis­tent­ly yields a pos­i­tive impact on long-term aca­d­e­m­ic suc­cess is thus an impor­tant issue; how­ev­er, the answer to this ques­tion has been some­what controversial.

Read More

Will digital therapeutics complement or replace stimulant medications to address inattention and “silent” cognitive issues?

By SharpBrains | January 29, 2020

___ Akili Inter­ac­tive: Dig­i­tal pedi­atric ADHD ther­a­peu­tic per­forms well with or with­out accom­pa­ny­ing stim­u­lant ther­a­py (Mobi­Health News): “Dig­i­tal ther­a­peu­tic com­pa­ny Akili Inter­ac­tive has announced the first results of an open-label, mul­ti­site pedi­atric ADHD tri­al pro­vid­ing some patients with the company’s video game-like treat­ment along­side a stim­u­lant med­ica­tion. Accord­ing to the com­pa­ny, both those who received…

Read More

Update: Humankind’s evolving quest to enhance the brain and the mind

By SharpBrains | January 27, 2020

___ Time for the first Sharp­Brains’ e‑newsletter in the new decade, fea­tur­ing a range of inspir­ing and (most­ly) promis­ing news about humankind’s evolv­ing quest to enhance the brain and the mind, and a few fun brain teasers :-) New think­ing: The Neu­ro­Gen­er­a­tion and Humankind’s Quest to Enhance the Brain UCSF to open inno­v­a­tive neu­rol­o­gy clin­ic to address…

Read More

Study: Having ADHD costs $1.1 million in lower lifetime earnings, even when “treated”

By Dr. David Rabiner | January 14, 2020

 Rel­a­tive­ly few stud­ies have exam­ined the impact of child­hood ADHD on long-term finan­cial out­comes, even though becom­ing self-sup­­port­ing and attain­ing finan­cial inde­pen­dence is an impor­tant devel­op­men­tal task. An espe­cial­ly com­pre­hen­sive look at this issue is pro­vid­ed in a study by Pel­ham et al pub­lished recent­ly in the Jour­nal of Con­sult­ing and Clin­i­cal Psy­chol­o­gy. The Study: Participants…

Read More